.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,817,656

« Back to Dashboard

Claims for Patent: 5,817,656

Title: Mental disorders
Abstract:2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders. The compound has the following structure: ##STR1##
Inventor(s): Beasley, Jr.; Charles M. (Indianapolis, IN), Chakrabarti; Jiban Kumar (Frimley, GB2), Hotten; Terrence Michael (Hants, GB2), Tupper; David Edward (Reading, GB2)
Assignee: Eli Lilly and Company (Indianapolis, IN) Eli Lilly and Company Limited (Basingstoke, GB2)
Application Number:08/748,293
Patent Claims: 1. A method of treating a patient suffering from or susceptible to a pathologic psychological condition selected from the group consisting of Unspecified Mental Retardation; Attention-Deficit Hyperactivity Disorder; Conduct Disorder, Undifferentiated Type; Chronic Motor or Vocal Tic Disorder; Transient Tic Disorder; Tic Disorder NOS; Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Depression; Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, Uncomplicated; Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Depression; Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, Uncomplicated; Bipolar Disorder, Mixed, Severe, without Psychotic Features; Bipolar Disorder, Manic, Severe, without Psychotic Features; Bipolar Disorder, Depressed, Severe, without Psychotic Features; Major Depression, Single Episode, Severe, without Psychotic Features; Major Depression, Recurrent, Severe, without Psychotic Features; Multi-infarct Dementia, with Depression; Multi-Infarct Dementia, Uncomplicated; Senile Dementia NOS; Presenile Dementia NOS; Dementia; Organic Mood Disorder; Organic Personality Disorder; Organic Mental Disorder; Body Dysmorphic Disorder; Hypochondriasis; Somatization Disorder; Undifferentiated Somatoform Disorder; Somatoform Disorder NOS; Intermittent Explosive Disorder; Kleptomania; Pathological Gambling; Pyromania; Trichotillomania; and Impulse-Control Disorder NOS; comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition.

2. A method of claim 1 wherein the condition is Unspecified Mental Retardation; Attention-Deficit Hyperactivity Disorder; Conduct Disorder, Undifferentiated Type; Organic Mood Disorder; Organic Personality Disorder; Organic Mental Disorder; Chronic Motor or Vocal Tic Disorder; Transient Tic Disorder; or Tic Disorder NOS.

3. A method of claim 1 wherein the condition is Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Depression; Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Depression; Multi- infarct Dementia, with Depression; Senile Dementia NOS; Presenile Dementia NOS; or Dementia.

4. A method of claim 1 wherein the condition is Bipolar Disorder, Mixed, Severe, without Psychotic Features; Bipolar Disorder, Manic, Severe, without Psychotic Features; Bipolar Disorder, Depressed, Severe, without Psychotic Features; Major Depression, Single Episode, Severe, without Psychotic Features; or Major Depression, Recurrent, Severe, without Psychotic Features.

5. A method of claim 1 wherein the condition is Body Dysmorphic Disorder; Hypochondriasis; Somatization Disorder; Undifferentiated Somatoform Disorder; Somatoform Disorder NOS; Intermittent Explosive Disorder; Kleptomania; Pathological Gambling; Pyromania; Trichotillomania; or Impulse-Control Disorder NOS.

6. A method of claim 1 wherein the effective amount is from 1 to 20 mg per day.

7. A method of treating a patient suffering from or susceptible to a pathologic psychological condition selected from the group consisting of Mental Retardation, Severity Unspecified; Attention-Deficit/Hyperactivity Disorder; Disruptive Behavior Disorder NOS; Chronic Motor or Vocal Tic Disorder; Transient Tic Disorder; Tic Disorder NOS; Dementia of the Alzheimer's Type, With Late Onset, With Depressed Mood; Dementia of the Alzheimer's Type, With Late Onset, Uncomplicated; Dementia of the Alzheimer's Type, With Early Onset, With Depressed Mood; Dementia of the Alzheimer's Type, With Early Onset, Uncomplicated; Bipolar I Disorder, Most Recent Episode Mixed, Severe Without Psychotic Features; Bipolar I Disorder, Most Recent Episode Manic, Severe Without Psychotic Features; Bipolar I Disorder, Most Recent Episode Depressed, Severe Without Psychotic Features; Major Depressive Disorder, Single Episode, Severe Without Psychotic Features; Major Depressive Disorder, Recurrent, Severe Without Psychotic Features; Vascular Dementia, With Depressed Mood; Vascular Dementia, Uncomplicated; Dementia Due to a Medical Condition; Mood Disorder Due to a Medical Condition; Personality Change Due to a Medical Condition; Dementia NOS; Body Dysmorphic Disorder; Hypochondriasis; Somatization Disorder; Undifferentiated Somatoform Disorder; Somatoform Disorder NOS; Intermittent Explosive Disorder; Kleptomania; Pathological Gambling; Pyromania; Trichotillomania; and Impulse-Control Disorder NOS; comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition.

8. A method of claim 7 wherein the effective amount is from 1 to 20 mg per day.

9. A method of treating a patient suffering from or susceptible to the pathologic psychological condition called Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Delirium, comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition.

10. The method of claim 9 wherein the effective amount is from 1 to 20 mg per day.

11. A method of treating a patient suffering from or susceptible to the pathologic psychological condition called Personality Disorder, Schizoid, comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition.

12. A method of treating a patient suffering from or susceptible to the pathologic psychological condition called Personality Disorder, Schizotypal, comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid additional salt thereof, that is effective to treat the condition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc